AYTU Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

12.51M

-22.89%

-0.600

-561.54%

13.39M

-27.46%

-0.465

-321.43%

15.92M

+5.16%

-0.275

-90.58%

Estimates Revision

The market is revising Downward the revenue expectations for Aytu BioPharma, Inc. (AYTU) for FY2026, with the revenue forecasts being adjusted by -8.94% over the past three months. During the same period, the stock price has changed by 0.43%.

Revenue Estimates for FY2026

Revise Downward

-8.94%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-30.06%

In Past 3 Month

Stock Price

Go Up

+0.43%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.340

Low

7.00

Averages

9.17

High

12.50

Current: 2.340

Low

7.00

Averages

9.17

High

12.50

Maxim

Buy

maintain

$9 -> $7

2025-09-25

Reason

Maxim

Price Target

$9 -> $7

2025-09-25

maintain

Buy

Reason

Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares. The firm cites the company's Q4 and adjusted EBITDA miss, and while the quarter was the 9th straight quarter of positive adjusted EBITDA, its base business - ADHD+pediatrics - has effectively peaked, the analyst tells investors in a research note. Maxim adds however that in June, Aytu announced it signed an exclusive commercialization agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA, and the firm believes that EXXUA is a transformational asset that can accelerate growth beyond the current ADHD franchise.

Maxim

Buy

downgrade

$9 -> $7

2025-09-24

Reason

Maxim

Price Target

$9 -> $7

2025-09-24

downgrade

Buy

Reason

Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares.

Lake Street

Buy

initiated

2025-07-01

Reason

Lake Street

Price Target

2025-07-01

initiated

Buy

Reason

Lake Street initiated coverage of Aytu BioPharma with a Buy rating and $8 price target. The firm beleives new entrants can make a dent in the crowded antidepressant market, particularly those that have some level of differentiation, the analyst tells investors in a research note. The firm's research indicates strong interest in Aytu's EXXUA as an alternative for patients with major depressive disorder, and says the launch will materially alter Aytu's financial profile, powering revenues to record levels already in FY27. Lake Street adds that substantial upside remains as generic overhang is resolved "one way or the other" and the EXXUA launch performance ramps at or above expectations.

Valuation Metrics

The current forward P/E ratio for Aytu Biopharma Inc (AYTU.O) is -2.53, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Aytu Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.89

Current PE

-2.53

Overvalued PE

4.40

Undervalued PE

-8.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.47

Current EV/EBITDA

-2.38

Overvalued EV/EBITDA

8.42

Undervalued EV/EBITDA

-11.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.41

Current PS

0.40

Overvalued PS

0.88

Undervalued PS

-0.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 541.02% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 541.02% over the last month.

Sold

Bought

AYTU News & Events

Events Timeline

No data

News

9.5

11-19NASDAQ.COM

Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday

9.5

11-14Yahoo Finance

Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Summary: Robust Performance of ADHD Portfolio

9.5

11-14NASDAQ.COM

Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close

People Also Watch

Frequently Asked Questions

What is Aytu Biopharma Inc (AYTU) stock price today?

The current price of AYTU is 2.34 USD — it has increased 1.74 % in the last trading day.

What is Aytu Biopharma Inc (AYTU)'s business?

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

What is the price predicton of AYTU Stock?

What is Aytu Biopharma Inc (AYTU)'s revenue for the last quarter?

Aytu Biopharma Inc revenue for the last quarter amounts to 13.89M USD, decreased -16.21 % YoY.

What is Aytu Biopharma Inc (AYTU)'s earnings per share (EPS) for the last quarter?

Aytu Biopharma Inc. EPS for the last quarter amounts to -0.08 USD, decreased -46.67 % YoY.

What changes have occurred in the market's expectations for Aytu Biopharma Inc (AYTU)'s fundamentals?

How many employees does Aytu Biopharma Inc (AYTU). have?

Aytu Biopharma Inc (AYTU) has 82 emplpoyees as of December 15 2025.

What is Aytu Biopharma Inc (AYTU) market cap?

Today AYTU has the market capitalization of 23.43M USD.